Inozyme price target raised to $16 from $14 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm’s price target on Inozyme (INZY) to $16 from $14 and keeps a Buy rating on the shares. The firm, which says Inozyme announced “solid” interim data from its open-label Phase 1b ENERGY-1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency, points out that it uses the net present value of its revenue forecasts through 2030 and assumes 40% odds of success for INZ-701 in ENPP1 Deficiency and 30% odds for INZ-701 in ABCC6 Deficiency to arrive at its price target